CD40 Ligand

CD40 Ligand Overview

English NameCD40 ligandApproved Drugs0
Drugs in Clinical Trials14Target SynonymCD154 Antigen,HCD40L,CD154,TNFSF5,CD40L,CD40 ligand, soluble form,CD40 ligand, membrane form,Tumor necrosis factor ligand superfamily member 5,T-cell antigen Gp39,CD40-L,CD40LG,TNF-Related Activation Protein,Tumor Necrosis Factor (Ligand) Superfamily Member 5,T-B Cell-Activating Molecule,T-BAM,HIGM1,Gp39,IMD3,IGM,CD40 Ligand,CD40 Antigen Ligand,TRAP,Tumor Necrosis Factor (Ligand) Superfamily, Member 5 (Hyper-IgM Syndrome),Hyper-IgM Syndrome,sCD40L
Highest Development StagePhase 3 Clinical
English NameCD40 ligand
Target SynonymCD154 Antigen,HCD40L,CD154,TNFSF5,CD40L,CD40 ligand, soluble form,CD40 ligand, membrane form,Tumor necrosis factor ligand superfamily member 5,T-cell antigen Gp39,CD40-L,CD40LG,TNF-Related Activation Protein,Tumor Necrosis Factor (Ligand) Superfamily Member 5,T-B Cell-Activating Molecule,T-BAM,HIGM1,Gp39,IMD3,IGM,CD40 Ligand,CD40 Antigen Ligand,TRAP,Tumor Necrosis Factor (Ligand) Superfamily, Member 5 (Hyper-IgM Syndrome),Hyper-IgM Syndrome,sCD40L
Approved Drugs0
Drugs in Clinical Trials14
Highest Development StagePhase 3 Clinical

CD40 Ligand Background

CD40 ligand is also known as CD40L, CD154, TNFSF5 and T-cell antigen Gp39, is a single-pass type I I membrane protein which belongs to the TNF superfamily of molecules. CD40 ligand is expressed predominantly on activated CD4+ T lymphocytes, and also found in other types of cells, including platelets, mast cells, macrophages, basophils, NK cells, B lymphocytes, as well as non-haematopoietic cells (smooth muscle cells, endothelial cells, and epithelial cells). Although all monomeric, dimeric and trimeric forms of soluble CD40 ligand can bind to CD40, the trimeric form of soluble CD40 ligand has the most potent biological activity through oligomerization of cell surface CD40, a common feature of TNF receptor family members. CD40 ligand binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In general, CD40 ligand plays the role of a costimulatory molecule and induces activation in APC in association with T cell receptor stimulation by MHC molecules on the APC. In total CD40 ligand has three binding partners: CD40, α5β1 integrin and αIIbβ3. CD40 ligand regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper IgM syndrome.

CD40 Ligand Synonyms

CD40LG,CD154,CD40L,HIGM1,IGM,IMD3,T-BAM,TNFSF5,TRAP,gp39

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Dapirolizumab pegolAnti-CD40L-Fab; Anti-CD40L-Fab-PEG; CDP-7657; CD40L - Fab; BIIB-133Phase 3 ClinicalBiogen Inc, UcbAutoimmune Diseases; Connective Tissue Diseases; Immune System Diseases; Lupus Erythematosus, Systemic; Skin and Connective Tissue Diseases
Details
DazodalibepVIB-4920; MEDI-4920; HZN-4920(Horizon Therapeutics); UNII-HN5US76BWF; WHO-11399Phase 3 ClinicalHorizon Therapeutics PLC, Medimmune LlcArthritis, Rheumatoid; Graft Rejection; Lupus Nephritis; Rejection of renal transplantation; Sjogren's Syndrome; Sjogren-Larsson Syndrome
Details
FrexalimabINX-021; SAR-441344Phase 3 ClinicalImmunext IncDiabetes Mellitus, Type 1; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Lupus Erythematosus, Systemic; Multiple Sclerosis; Nephrosis; Rejection of renal transplantation; Sjogren's Syndrome; Sjogren-Larsson Syndrome
Details
Anti-CD40L antibody (Bristol-Myers Squibb)Phase 2 ClinicalBristol-Myers Squibb CompanyImmunologic Deficiency Syndromes
Details
TegoprubartAT-1501Phase 2 ClinicalAls Therapy Development InstituteAmyotrophic Lateral Sclerosis; Diabetes Mellitus, Type 1; Glomerulonephritis, IGA; Rejection of renal transplantation
Details
Delolimogene mupadenorepvecLOAd-703Phase 2 ClinicalLokon Pharma, Uppsala UniversityBiliary Tract Neoplasms; Colorectal Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms
Details
TNX-1500TNX-1500Phase 2 ClinicalTonix Pharmaceuticals Holding CorpAutoimmune Diseases; Autoimmune Diseases of the Nervous System; Rejection of renal transplantation; Rejection of organ transplantation
Details
Base-edited hematopoietic stem and progenitor cells therapy (NIAID)Phase 2 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)Hyper-IgM Immunodeficiency Syndrome, Type 1
Details
CD40 ligand expressing MSLN-CAR T cellsPhase 2 ClinicalPla General HospitalSolid tumours
Details
LetolizumabBMS-986004; BMS2h-572-633-CT-L2Phase 1 ClinicalBristol-Myers Squibb CompanyGraft vs Host Disease; Purpura, Thrombocytopenic, Idiopathic
Details
MEM-288MEM-288Phase 1 ClinicalMemgenCarcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
IBI355IBI-355Phase 1 ClinicalLupus Erythematosus, Systemic; Sjogren's Syndrome
Details
CD40L-augmented Tumor Infiltrating Lymphocytes (H Lee Moffitt Cancer Center & Research Institute)Phase 1 ClinicalH Lee Moffitt Cancer Center & Research InstituteCarcinoma, Non-Small-Cell Lung
Details
Lu-AG22515APB-A1; Lu-AG22515Phase 1 ClinicalAprilBio Co LtdGraves Ophthalmopathy; Neuromyelitis Optica
Details
  • Overview
  • Product List
  • Clinical Drug Information